Loading
Telisotuzumab vedotin (Emrelis) is the first c-MET-directed ADC, approved in 2025 for lung cancer with high c-MET protein.
Telisotuzumab vedotin (Emrelis) is an anti-c-MET antibody linked to the microtubule inhibitor MMAE through a cleavable mc-vc-PABC linker; it needs no MET mutation, only high c-MET protein on the tumour surface, which it uses as a delivery address. It received accelerated approval in May 2025 for previously treated non-squamous NSCLC with high c-MET overexpression on the strength of LUMINOSITY (objective response rate around 35 percent), and is given at 1.9 mg/kg every 2 weeks. It is the first c-MET-directed ADC to reach approval, after Breakthrough Therapy designation in 2022. Peripheral neuropathy, fatigue, decreased appetite, peripheral oedema and nausea are the main toxicities, and interstitial lung disease and ocular symptoms are monitored. The confirmatory TeliMET NSCLC-01 trial is ongoing. It treats lung cancers that overproduce c-MET protein by using that protein as a doorway.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Anti-c-MET antibody with MMAE. Connects to MET.
1.Antibody binds c-MET on the tumour cell surface
Source: www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications. Doses are for orientation; the current label governs.
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. FDA accelerated approval 2025 for c-Met overexpressing NSCLC.
Covered under the medical benefit with prior authorisation confirming diagnosis, biomarker status and line of therapy; site-of-care policies may steer infusions away from hospital outpatient departments. c-Met IHC result required.
20% Part B coinsurance on a high-cost infusion adds up quickly: Medigap Plan G or N, Medicare Advantage maximum out-of-pocket, Medicaid dual eligibility, or a charity fund are the usual buffers.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
Sources: NICE search: telisotuzumab vedotin. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
Breakthrough Therapy designation, c-MET overexpressing NSCLC source
Treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy.
Accelerated approval, previously treated c-MET-high non-squamous NSCLC (LUMINOSITY) The confirmatory requirement was still open 1.3 years later, when the FDA's table was read. source
| Region | Year | Indication |
|---|---|---|
| US | 2025 | c-MET-high non-squamous NSCLC, previously treated (accelerated) |
| Adverse event |
|---|
| Peripheral neuropathy |
| Fatigue |
| Decreased appetite |
| Peripheral oedema |
| Nausea |
Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United States | Medicare Part B (physician-administered); commercial plans per formulary | not disclosed | - |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Telisotuzumab vedotin" OR ABSTRACT:"Telisotuzumab vedotin" OR TITLE:"Emrelis" OR ABSTRACT:"Emrelis") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Telisotuzumab vedotin, not a curated reading list.
Shares c-Met protein overexpression (IHC 3+ in >= 50% of tumour cells), MET amplification (gene copy number), MET exon 14 skipping mutation, MET amplification (bypass resistance).
Shares c-Met protein overexpression (IHC 3+ in >= 50% of tumour cells), MET amplification (gene copy number), MET exon 14 skipping mutation, MET.
Shares MET exon 14 skipping mutation, MET exon 14 and MET-amplified non-small-cell lung cancer, MET, Receptor tyrosine kinase activation.
Shares MET amplification (gene copy number), MET exon 14 skipping mutation, MET exon 14 and MET-amplified non-small-cell lung cancer, MET.
Shares MET amplification (gene copy number), MET amplification (bypass resistance), MET, Receptor tyrosine kinase activation.
Shares MET amplification (gene copy number), MET exon 14 skipping mutation, MET exon 14 and MET-amplified non-small-cell lung cancer, MET.
Shares MET amplification (bypass resistance), MET exon 14 and MET-amplified non-small-cell lung cancer, MET, Lung cancer (all types).
Shares MET amplification (gene copy number), MET amplification (bypass resistance), MET, Receptor tyrosine kinase activation.